Galapagos Signs a Worldwide Development & Commercialization Agreement with Evotec for Fibrotic Diseases

 Galapagos Signs a Worldwide Development & Commercialization Agreement with Evotec for Fibrotic Diseases

Evotec Signs a Research Agreement with Indivumed to Develop Precision Therapies for Colorectal Cancer (CRC)

Shots:

  • Evotec to receive upfront, milestones and royalties on sales of product from Galapagos. Galapagos to get WW commercialization rights for developed product, will be responsible for future development and have access to Evotec’s technology till pre-clinical phase
  • The focus of the collaboration is to conduct pre-clinical trial for the development of therapies for fibrotic diseases of the liver and other organs using Evotec’s technology
  • In H1’19, Evotec and Fibrocor globally collaborated to develop therapies for idiopathic pulmonary fibrosis (IPF) and other indications

Click hereto read full press release/ article | Ref: Galapagos | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post